Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
Company profile
Ticker
LLY, LLY-GF, LLY-GM, LLY-SE
Exchange
Website
CEO
David Ricks
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LILLY ELI & CO, LILLY ELI & CO ET AL
SEC CIK
Corporate docs
Subsidiaries
Akouos Securities Corporation • Akouos, Inc. • Alnara Pharmaceuticals, Inc. • Andean Technical Operations • ARMO Biosciences, Inc. • Avid Radiopharmaceuticals, Inc. • CoLucid Pharmaceuticals, Inc. • Compania Farmaceutica Eli Lilly de Centro America S.A. • Dermira, Inc. • DICE Alpha Inc. ...
IRS number
350470950
LLY stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
9 May 24
SD
Conflict minerals disclosure
3 May 24
10-Q
2024 Q1
Quarterly report
30 Apr 24
8-K
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
30 Apr 24
PX14A6G
Letter to shareholders
11 Apr 24
PX14A6G
Letter to shareholders
28 Mar 24
PX14A6G
Letter to shareholders
28 Mar 24
PX14A6G
Letter to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
22 Mar 24
DEF 14A
Definitive proxy
22 Mar 24
Transcripts
LLY
Earnings call transcript
2024 Q1
30 Apr 24
LLY
Earnings call transcript
2023 Q4
6 Feb 24
LLY
Earnings call transcript
2023 Q3
2 Nov 23
LLY
Earnings call transcript
2023 Q2
8 Aug 23
LLY
Earnings call transcript
2023 Q1
27 Apr 23
LLY
Earnings call transcript
2022 Q4
2 Feb 23
LLY
Earnings call transcript
2022 Q3
1 Nov 22
LLY
Earnings call transcript
2022 Q2
4 Aug 22
LLY
Earnings call transcript
2022 Q2
7 Jun 22
LLY
Earnings call transcript
2022 Q1
28 Apr 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.46 bn | 2.46 bn | 2.46 bn | 2.46 bn | 2.46 bn | 2.46 bn |
Cash burn (monthly) | 119.47 mm | 90.48 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 189.14 mm | 143.24 mm | n/a | n/a | n/a | n/a |
Cash remaining | 2.27 bn | 2.32 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 19.0 | 25.6 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
54.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2784 |
Opened positions | 355 |
Closed positions | 483 |
Increased positions | 1047 |
Reduced positions | 1037 |
13F shares | Current |
---|---|
Total value | 275.26 tn |
Total shares | 513.41 mm |
Total puts | 1.83 mm |
Total calls | 1.24 mm |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 71.61 mm | $41.74 tn |
PNC PNC Financial Services | 51.71 mm | $30.14 tn |
STT State Street | 33.79 mm | $19.70 tn |
FMR | 32.85 mm | $19.15 tn |
Capital World Investors | 26.95 mm | $15.71 tn |
Primecap Management | 22.20 mm | $12.94 tn |
T. Rowe Price | 21.83 mm | $12.72 bn |
JPM JPMorgan Chase & Co. | 19.27 mm | $11.24 tn |
MS Morgan Stanley | 12.66 mm | $7.38 tn |
Wellington Management | 11.78 mm | $6.87 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Alvarez Ralph | Common Stock | Grant | Acquire A | No | No | 750.77 | 16 | 12.01 k | 54,029 |
15 Apr 24 | Hedley Mary Lynne | Common Stock | Grant | Acquire A | No | No | 750.77 | 13 | 9.76 k | 1,477 |
15 Apr 24 | Luciano Juan R | Common Stock | Grant | Acquire A | No | No | 750.77 | 20 | 15.02 k | 15,678 |
15 Apr 24 | Kimberly H Johnson | Common Stock | Grant | Acquire A | No | No | 750.77 | 13 | 9.76 k | 2,627 |
15 Apr 24 | Greene-Sulzberger Gabrielle | Common Stock | Grant | Acquire A | No | No | 750.77 | 13 | 9.76 k | 2,128 |
News
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
17 May 24
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
17 May 24
Evaluating Eli Lilly and Co Against Peers In Pharmaceuticals Industry
17 May 24
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
16 May 24
Eli Lilly's QWINT-2 And QWINT-4 Phase 3 Trials Of Once-weekly Insulin Efsitora In Type 2 Diabetes Patients Using Insulin For First Time And Require Multiple Daily Injections, Efsitora Showed Non-Inferior A1C Reduction Vs. Most Commonly Used Daily Insulin
16 May 24
Press releases
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
17 May 24
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
16 May 24
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
8 May 24
Lilly Declares Second-Quarter 2024 Dividend
6 May 24
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
30 Apr 24